Pharmaceuticals

FDA approves Biocon Biologics’ Eylea biosimilar Yesafili to treat multiple eye diseases

bexib
By bexib 0 Min Read

Yesafili’s approval marks Biocon’s entry into the US ophthalmology market, following previous approvals in Europe and the UK.

You Might Also Like

Femasys CEO Discusses FemaSeed Pivotal Trial Results and the History of FemBlock Contraception

Gene therapy that costs over $4 million?How can payers adapt to the new reality of expensive “cures”?

How should biotech companies plan their strategies for 2025?

FDA Approves Merz Aesthetics’ Xeomin for Simultaneous Treatment of Upper Facial Wrinkles

Efcitra demonstrates non-inferiority to insulin glargine and degludec in type 2 diabetes

Share This Article
Previous Article Dismantling The Cash-flow Narrative: Real Estate vs. Bitcoin
Next Article Bean and Corn Prices, Drought Insurance Options, Technology Integration, March 20, 2024 – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

52% of executives say they plan to use agents
Banking
Blueprint for 2025: Stronger trade policy
Manufacturing
China’s seapower expands as US shipyards decline
Manufacturing
Print advertising is an e-commerce opportunity
Retail & E-commerce